Certara Inc. (CERT): Price and Financial Metrics

Certara Inc. (CERT): $17.44

0.23 (-1.30%)

POWR Rating

Component Grades

Momentum

D

Stability

B

Sentiment

Quality

C

Add CERT to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#163 of 363

in industry

CERT Price/Volume Stats

Current price $17.44 52-week high $24.96
Prev. close $17.67 52-week low $11.81
Day low $17.28 Volume 520,100
Day high $17.80 Avg. volume 545,778
50-day MA $17.79 Dividend yield N/A
200-day MA $16.34 Market Cap 2.79B

CERT Stock Price Chart Interactive Chart >


Certara Inc. (CERT) Company Bio


Certara, Inc. engages in the provision of software and technology enables services for drug developers. It offers cell and gene therapy, clinical pharmacology, complex biologics, decision analytics and modeling, drug development and regulatory strategy, and model-based analysis services. The company was founded on June 27, 2017 and is headquartered in Princeton, NJ.


CERT Latest News Stream


Event/Time News Detail
Loading, please wait...

CERT Latest Social Stream


Loading social stream, please wait...

View Full CERT Social Stream

Latest CERT News From Around the Web

Below are the latest news stories about CERTARA INC that investors may wish to consider to help them evaluate CERT as an investment opportunity.

Certara Acquires Applied BioMath Expanding Its Biosimulation Portfolio to Industrialize New Capabilities for Optimal Dosing for Novel Therapies

Combined organization establishes the life sciences industry’s largest quantitative systems pharmacology (QSP) center of excellence contributing to faster and more effective medicine development.PRINCETON, N.J., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT) today announced it has acquired Applied BioMath, an industry-leader in providing model-informed drug discovery and development support to help accelerate and de-risk therapeutic research and development (R&D). Together, Certa

Yahoo | December 13, 2023

Certara introduces Simcyp™ Biopharmaceutics software to increase efficiency of novel and generic drug formulation & development

Simcyp Biopharmaceutics helps drug developers replace costly clinical bioequivalence studies and optimize formulations for complex therapiesPRINCETON, N.J., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the introduction of Simcyp™ Biopharmaceutics software. It is designed for use by biopharmaceutic, formulation, and CMC scientists to aid in formulating complex novel and generic small molecule medicines quickly and cost effective

Yahoo | November 21, 2023

Certara, Inc. (NASDAQ:CERT) Q3 2023 Earnings Call Transcript

Certara, Inc. (NASDAQ:CERT) Q3 2023 Earnings Call Transcript November 8, 2023 Certara, Inc. reports earnings inline with expectations. Reported EPS is $0.11 EPS, expectations were $0.11. Operator: Good day, and thank you for standing by. Welcome to the Certara Third Quarter 2023 Earnings Conference Call. [Operator Instructions] Please be advised that today’s conference is being […]

Yahoo | November 10, 2023

Q3 2023 Certara Inc Earnings Call

Q3 2023 Certara Inc Earnings Call

Yahoo | November 9, 2023

Certara, Inc. (CERT) Q3 Earnings Meet Estimates

Certara, Inc. (CERT) delivered earnings and revenue surprises of 0% and 0.45%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 9, 2023

Read More 'CERT' Stories Here

CERT Price Returns

1-mo -5.53%
3-mo 8.93%
6-mo 26.84%
1-year -27.60%
3-year -37.85%
5-year N/A
YTD -0.85%
2023 9.46%
2022 -43.46%
2021 -15.72%
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!